- Home
- TBLA vs IMTX Comparison
TBLA vs IMTX Comparison
Compare TBLA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLA
- IMTX
- Stock Information
- Founded
- TBLA 2007
- IMTX N/A
- Country
- TBLA United States
- IMTX Germany
- Employees
- TBLA N/A
- IMTX N/A
- Industry
- TBLA Computer Software: Programming Data Processing
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBLA Technology
- IMTX Health Care
- Exchange
- TBLA Nasdaq
- IMTX Nasdaq
- Market Cap
- TBLA 976.2M
- IMTX 865.5M
- IPO Year
- TBLA N/A
- IMTX N/A
- Fundamental
- Price
- TBLA $3.57
- IMTX $10.19
- Analyst Decision
- TBLA Strong Buy
- IMTX Strong Buy
- Analyst Count
- TBLA 5
- IMTX 4
- Target Price
- TBLA $4.50
- IMTX $13.67
- AVG Volume (30 Days)
- TBLA 1.3M
- IMTX 930.5K
- Earning Date
- TBLA 11-05-2025
- IMTX 11-17-2025
- Dividend Yield
- TBLA N/A
- IMTX N/A
- EPS Growth
- TBLA N/A
- IMTX N/A
- EPS
- TBLA 0.04
- IMTX N/A
- Revenue
- TBLA $1,817,019,000.00
- IMTX $152,823,253.00
- Revenue This Year
- TBLA $8.31
- IMTX N/A
- Revenue Next Year
- TBLA $4.65
- IMTX $13.53
- P/E Ratio
- TBLA $88.02
- IMTX N/A
- Revenue Growth
- TBLA 12.01
- IMTX 83.61
- 52 Week Low
- TBLA $2.50
- IMTX $3.30
- 52 Week High
- TBLA $4.30
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- TBLA 62.85
- IMTX 58.23
- Support Level
- TBLA $3.41
- IMTX $9.99
- Resistance Level
- TBLA $3.67
- IMTX $10.70
- Average True Range (ATR)
- TBLA 0.10
- IMTX 0.57
- MACD
- TBLA 0.04
- IMTX -0.15
- Stochastic Oscillator
- TBLA 84.62
- IMTX 30.85
About TBLA Taboola.com Ltd.
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, United States, Germany, Rest of the world. It generates the majority of its revenue from the United States.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.